Nicholas C Chesnaye1, Franz Schaefer2, Jaap W Groothoff3, Fergus J Caskey4, James G Heaf5, Stella Kushnirenko6, Malcolm Lewis7, Reiner Mauel8, Elisabeth Maurer9, Jussi Merenmies10, Diamant Shtiza11, Rezan Topaloglu12, Natalia Zaicova13, Argyroula Zampetoglou14, Kitty J Jager1, Karlijn J van Stralen1. 1. ESPN/ERA-EDTA Registry and ERA-EDTA Registry, Amsterdam, Netherlands. 2. Division of Paediatric Nephrology, University of Heidelberg Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany. 3. Department of Pediatric Nephrology, Emma Children's Hospital AMC, Amsterdam, Netherlands. 4. Richard Bright Renal Unit, Bristol, UK. 5. Department of Nephrology, University of Copenhagen, Herlev, Denmark. 6. Department of Pediatric Nephrology, University of Kiev, Kyiv, Ukraine. 7. Manchester Children's Hospital, Manchester, UK. 8. Department of Pediatric Nephrology, University of Gent, Gent, Belgium. 9. Institute of Social and Preventive Medicine, Bern, Switzerland. 10. Department of Pediatric Nephrology and Transplantation, University of Helsinki, Helsinki, Finland. 11. Department of Pediatrics Nephrology Unit, University Hospital Centre 'Mother Tereza', Tirana, Albania. 12. Department of Pediatric Nephrology, Hacettepe University, Ankara, Turkey. 13. Institute of Mother and Child Care, Chisinau, Moldova. 14. Department of Pediatric Nephrology, 'A. and P. Kyriakou' Children's Hospital, Athens, Greece.
Abstract
BACKGROUND: Considerable disparities exist in the provision of paediatric renal replacement therapy (RRT) across Europe. This study aims to determine whether these disparities arise from geographical differences in the occurrence of renal disease, or whether country-level access-to-care factors may be responsible. METHODS: Incidence was defined as the number of new patients aged 0-14 years starting RRT per year, between 2007 and 2011, per million children (pmc), and was extracted from the ESPN/ERA-EDTA registry database for 35 European countries. Country-level indicators on macroeconomics, perinatal care and physical access to treatment were collected through an online survey and from the World Bank database. The estimated effect is presented per 1SD increase for each indicator. RESULTS: The incidence of paediatric RRT in Europe was 5.4 cases pmc. Incidence decreased from Western to Eastern Europe (-1.91 pmc/1321 km, P < 0.0001), and increased from Southern to Northern Europe (0.93 pmc/838 km, P = 0.002). Regional differences in the occurrence of specific renal diseases were marginal. Higher RRT treatment rates were found in wealthier countries (2.47 pmc/€10 378 GDP per capita, P < 0.0001), among those that tend to spend more on healthcare (1.45 pmc/1.7% public health expenditure, P < 0.0001), and among countries where patients pay less out-of-pocket for healthcare (-1.29 pmc/11.7% out-of-pocket health expenditure, P < 0.0001). Country neonatal mortality was inversely related with incidence in the youngest patients (ages 0-4, -1.1 pmc/2.1 deaths per 1000 births, P = 0.10). Countries with a higher incidence had a lower average age at RRT start, which was fully explained by country GDP per capita. CONCLUSIONS: Inequalities exist in the provision of paediatric RRT throughout Europe, most of which are explained by differences in country macroeconomics, which limit the provision of treatment particularly in the youngest patients. This poses a challenge for healthcare policy makers in their aim to ensure universal and equal access to high-quality healthcare services across Europe.
BACKGROUND: Considerable disparities exist in the provision of paediatric renal replacement therapy (RRT) across Europe. This study aims to determine whether these disparities arise from geographical differences in the occurrence of renal disease, or whether country-level access-to-care factors may be responsible. METHODS: Incidence was defined as the number of new patients aged 0-14 years starting RRT per year, between 2007 and 2011, per million children (pmc), and was extracted from the ESPN/ERA-EDTA registry database for 35 European countries. Country-level indicators on macroeconomics, perinatal care and physical access to treatment were collected through an online survey and from the World Bank database. The estimated effect is presented per 1SD increase for each indicator. RESULTS: The incidence of paediatric RRT in Europe was 5.4 cases pmc. Incidence decreased from Western to Eastern Europe (-1.91 pmc/1321 km, P < 0.0001), and increased from Southern to Northern Europe (0.93 pmc/838 km, P = 0.002). Regional differences in the occurrence of specific renal diseases were marginal. Higher RRT treatment rates were found in wealthier countries (2.47 pmc/€10 378 GDP per capita, P < 0.0001), among those that tend to spend more on healthcare (1.45 pmc/1.7% public health expenditure, P < 0.0001), and among countries where patients pay less out-of-pocket for healthcare (-1.29 pmc/11.7% out-of-pocket health expenditure, P < 0.0001). Country neonatal mortality was inversely related with incidence in the youngest patients (ages 0-4, -1.1 pmc/2.1 deaths per 1000 births, P = 0.10). Countries with a higher incidence had a lower average age at RRT start, which was fully explained by country GDP per capita. CONCLUSIONS: Inequalities exist in the provision of paediatric RRT throughout Europe, most of which are explained by differences in country macroeconomics, which limit the provision of treatment particularly in the youngest patients. This poses a challenge for healthcare policy makers in their aim to ensure universal and equal access to high-quality healthcare services across Europe.
Authors: Sophie Ploos van Amstel; Marlies Noordzij; Bradley A Warady; Francisco Cano; Jonathan C Craig; Jaap W Groothoff; Kenji Ishikura; Alicia Neu; Hesham Safouh; Hong Xu; Kitty J Jager; Franz Schaefer Journal: Pediatr Nephrol Date: 2017-12-22 Impact factor: 3.714